A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

Launched by LOCUS BIOSCIENCES · Aug 2, 2022

Keywords

ClinConnect Summary

The ELIMINATE Trial is a clinical study investigating a new treatment called LBP-EC01 for women who have acute urinary tract infections (UTIs) caused by a drug-resistant bacterium called E. coli. This study aims to find out if combining LBP-EC01 with antibiotics is more effective than using a placebo (a treatment with no active ingredients) along with antibiotics. To participate, women need to have had a UTI in the past year, provide a urine sample for testing, and show symptoms of an active UTI, like painful urination or frequent urges to go.

Participants in the trial can expect to be randomly assigned to either the treatment group or the placebo group. They'll need to follow specific guidelines, such as stopping any preventive antibiotic medications and avoiding other treatments for their UTI for the first ten days. The study involves regular visits and providing samples for testing over a six-month period. It’s important to note that certain individuals, like those with severe health issues or pregnant women, cannot participate in this study. If you think you might be eligible, this trial could offer a new option for treating your UTI.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • History of UTI in the past 12 months and prior or current uUTI caused by AMR E. coli (as single pathogen or part of polymicrobial infection where E. coli is the predominant pathogen). Please note that the current infection can be used to meet the requirement of AMR E. coli documentation.
• • Able to supply a mid-stream, clean catch urine sample for microbiological analysis.
• * Active acute uUTI infection defined by:
• • a. Evidence of pyuria: i. \>10 white blood cell (WBC)/mL3 on microscopic evaluation of spun, clean, mid-stream urine specimen or \>3 WBC/high power field on unspun clean, mid-stream urine specimen, AND/OR ii. Dipstick analysis of a clean, mid-stream urine specimen positive for leukocytes, AND b. At least 2 of the following signs or symptoms of UTI: dysuria, urinary frequency, urinary urgency, or suprapubic pain
• • Willing to comply with all aspects of study design including study restrictions, blood, urine, and stool sampling, and scheduled study visits.
• • All sexually active female patients of childbearing potential must use highly effective contraception during the study and until 2 weeks after the last dose of study drug treatment.
• • Agrees to STOP continuous low dose antimicrobial prophylaxis and/or will maintain the same practices for post-coital antimicrobial prophylaxis to prevent UTI, as during the prior 12-months, for the entire study duration (throughout the 6-month follow-up period or study discharge).
• • Agrees to not use any prescription or non-prescription medication for the microbiological or symptomatic treatment of the presenting acute uUTI for the first 10 days of the study.
• • Capable of providing their own signed informed consent form (ICF) prior to any study-related procedures being performed.
• • If participating in Part 1 of the study, agrees to fast for ≥2 h prior to first dose of study drug on Day 1/Visit 1 except for drinking 240 mL of water with study drug administration.
• Exclusion Criteria:
• • Signs or symptoms of systemic illness such as fever greater than 38° Centigrade/ Celsius, shaking chills, or other clinical manifestations suggestive of complicated UTI.
• • Treatment with other antibacterial drugs including those that are effective for treatment of the acute uUTI or prevention of recurrent UTI in the 5 days prior to Screening unless the recovered pathogen demonstrates resistance to the initial antibiotic and clinical symptoms persist. In postmenopausal women vaginal estrogen replacement therapy is permitted so long as patient meets all other eligibility criteria, that the dose and regimen has be stable for \> 3 months from Screening (D1/V1), and that there is no planned change to therapy through the 6-month follow-up period or study discontinuation.
• • Clinical symptoms for more than 5 days before Screening.
• • Presence of indwelling urinary bladder catheters, urinary tract anatomical abnormalities that increase UTI risk or lead to a post void residual (PVR) urine volume \> 150mL, poorly controlled diabetes mellitus (diagnosed but is not being treated/managed by a physician's care or HbA1c \>8), current symptomatic or larger than 5mm renal calculi, or advanced renal dysfunction (determined by eGFR \< 45 mL/min/1.73 m2). Patients with vaginal prolapse beyond the hymen with Valsalva (e.g., when coughing).
• • Individuals considered to be immunocompromised.
• • Clinically significant serious unstable physical illness that in the investigator's opinion prevents patient from completing the study or prevents interpretation or resolution of clinical symptoms.
• • Pregnant or nursing women.
• • Exposure to any investigational drugs or other phage therapy 30 days prior to Screening (D1/V1) or prior to participation in this study. Patients who participate in Part 1 are not eligible for participation in Part 2.
• • Allergies to excipients of the study drug or antibiotics.
• • History of autonomic dysreflexia.
• • History of intravenous (IV) drug abuse or is currently using or has positive results for drugs of abuse at screening.
• • Patients who reside in a long-term care facility.
• • Suspected or confirmed acute coronavirus disease 2019 (COVID-19) or recent COVID-19 infection with ongoing symptoms.